Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$265.58-0.77 (-0.29%)
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Trailing-twelve-month (TTM) revenue is $97.93 Billion with a year-over-year growth of +8.06%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-28 | $23,993,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-22 |
| Q4 FY2025Period ended 2025-12-28 | $24,564,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q1 FY2026Period ended 2026-03-29 | $24,062,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-22 |
| Q2 FY2026Period ended 2026-06-28 | $25,310,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-23 |
| TTM revenue | $97,929,000,000 |
Current P/S: $640,020,821,321 market capitalization ÷ $97,929,000,000 TTM revenue = 6.54x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-28.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-28): $25.31B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-14T13:20:46.727Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202021-01-02 · USD | FY20212022-01-02 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|---|---|---|
| Consumer | $14.4B | $14.6B | $15.0B | N/A | N/A | N/A |
| Innovative Medicine | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202021-01-02 · USD | FY20212022-01-02 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|---|---|---|
| Asia-Pacific, Africa | $15.1B | $17.3B | $16.8B | $13.8B | $13.6B | $14.0B |
| Europe | $19.0B | $23.6B | $23.4B | $20.4B |
$97.93B
$97.93 Billion
+8.06%
vs. $90.62B a year ago (TTM)
+2.93%
5 Year compound annual growth rate
1 Year
+8.06%
3 Year
+3.13%
5 Year
+2.93%
10 Year
+3.31%
15 Year
+3.03%
20 Year
+3.31%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $94.19B | +$5.37B | +6.05% |
| 2024 | $88.82B | +$3.66B | +4.30% |
| 2023 | $85.16B | +$5.17B | +6.46% |
| 2022 | $79.99B | +$1.25B | +1.59% |
| 2021 | $78.74B | ($3.84B) | (4.65%) |
| 2020 |
TTM Growth
+8.06%
3-Year CAGR
+3.13%
5-Year CAGR
+2.93%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-14T13:20:46.727Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $54.8B |
| $57.0B |
| $60.4B |
| Medical Devices | $23.0B | $27.1B | N/A | N/A | N/A | N/A |
|---|
| MedTech | N/A | N/A | $27.4B | $30.4B | $31.9B | $33.8B |
|---|
| Pharmaceutical | $45.2B | $52.1B | N/A | N/A | N/A | N/A |
|---|
| $20.2B |
| $21.5B |
| UNITED STATES | $43.1B | $47.2B | $48.6B | $46.4B | $50.3B | $53.8B |
|---|
| Western Hemisphere, excluding U.S. | $5.3B | $5.8B | $6.1B | $4.5B | $4.7B | $4.9B |
|---|
| $82.58B |
| +$525.00M |
| +0.64% |
| 2019 | $82.06B | +$478.00M | +0.59% |
| 2018 | $81.58B | +$5.13B | +6.71% |
| 2017 | $76.45B | +$4.56B | +6.34% |
| 2016 | $71.89B | +$1.82B | +2.59% |